Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences:
- Jefferies Biotech on the Bay Summit, March 12-13th: Alto management will participate in one-on-one meetings with investors during the conference.
- UBS Virtual CNS Day, March 18th: Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Monday, March 18, 2024, at 2:30 pm ET.
- Stifel 2024 Virtual CNS Days, March 19-20th: Dr.Etkin will participate in a fireside chat on Wednesday, March 20, 2024, at 11:30 am ET. Alto management will also participate in one-on-one meetings with investors during the conference.
The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307562812/en/
